10 / 18
Inst itut Català d'Oncologia
Institut Català d’Oncol gia
KEYNOTE-012
10
ORR by PD-L1 status
Non-responders
n
Responders
n
ORR, %
(95% CI)
CPS (tumor and
inflammatory cells)
PD-L1+
(N=60)
47
13
22 %
PD-L1–
(N=44)
42
2
4 %
•Chow LQ, et al. ASCO 2016 (Abstract No. 6010)
Tumor and inflammatory cells PD-L1 – Dako 22C3
Tumor PD-L1 expression alone was not associated with improved ORR, PFS, or OS with PEMBRO